Study of Molecular Docking, Molecular Dynamic and Toxicity Prediction of Several Quinoline Alkaloid Derivatives as a Bruton Tyrosine Kinase Inhibitor as Anti-Leukemia
Abstract
Quinoline alkaloid and its derivatives play a vital role in the development of new therapeutic agents. Cinnoline structure has similarities with quinoline alkaloid compound and has the potential to inhibit Bruton’s Tyrosine Kinase (BTK) in leukemia treatment. This research aims to study the interaction of several quinoline alkaloids with BTK and to predict the toxicity to ensure their safety. This study was carried out using computational studies, including molecular docking, molecular dynamics simulation, and toxicity prediction, to assess the compound’s activity towards BTK and their toxicity. Molecular docking simulations showed that ten compounds (S1, S2, S4, S5, S8, S13, S14, S16, S17, and S20) had the best affinity to BTK. Molecular dynamics simulations to these ten compounds showed that only seven compounds (S1, S5, S8, S13, S16, S17, and S20) could stabilize the interaction towards BTK with RMSD and RMSF value of 0.5 ± 2 Å and 0.5 ± 6, 5 Å, respectively. Toxicity prediction results showed that these quinoline alkaloids had various toxicity characteristics, but most were not carcinogens and mutagens (S4, S5, S6, S7, S8, S10 S11, S12, S14, and S15). It can be concluded that Yukositrin (S8) has the most potential affinity towards BTK, which can be used as anti-leukemia with low toxicity.
Keywords: anti-leukemia, Bruton Tyrosine Kinase, docking, MD, quinoline alkaloids
Keywords:
anti-leukemia, Bruton Tyrosine Kinase, docking, MD, quinoline alkaloidsDOI
https://doi.org/10.22270/jddt.v11i6-S.5135References
Data and Information Center, the Ministry of Health Republic of Indonesia, 2015. Available at: http://www.pusdatin.kemkes.go.id/folder/view/01/structure-publikasi-pusdatin-profil-kesehatan.html [accessed 02 July 2017]
Muttaqin FZ, Fakih TM, and Muhammad HN: Molecular docking, molecular dynamics, and in silico toxicity prediction studies of coumarin, n-oxalylglycine, organoselenium, organosulfur, and pyridine derivatives as histone lysine demethylase inhibitors, Asian Journal of Pharmaceutical and Clinical Research 2017; 10(12):212-215. https://doi.org/10.22159/ajpcr.2017.v10i12.19348
Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, Steggerda SM, Coleman M, Leslie C, and Wang YL: Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014 Jun 12; 370(24):2352-4. Epub 2014 May 28. https://doi.org/10.1056/NEJMc1402716
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, and O'Brien S: The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 7; 125(19):2915-22. Epub 2015 Mar 9. https://doi.org/10.1182/blood-2014-09-585869
Ivanescu AM, Oprea M, Turbatu A, Colita A, and Lupu AR: Ibrutinib, a novel agent in relapsed or refractory chronic lymphocytic leukemia. Maedica (Buchar). 2014 Jun; 9(2):217-8.
Maas A and Hendriks RW: Role of Bruton's tyrosine kinase in B cell development. Dev Immunol. 2001; 8(3-4):171-81. https://doi.org/10.1155/2001/28962
Wiestner A: Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013 Jan 1 https://doi.org/10.1200/JCO.2012.44.4281
(1):128-30. DOI: 10.1200/JCO.2012.44.4281. Epub 2012 Oct 8. https://doi.org/10.1200/JCO.2012.44.4281
Young RM and Staudt LM: Ibrutinib treatment of CLL: the cancer fights back. Cancer Cell. 2014; 26(1):11-3. https://doi.org/10.1016/j.ccr.2014.06.023
Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, and Woyach JA: The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov. 2018 Oct; 8(10):1300-1315. Epub 2018 Aug 9. https://doi.org/10.1158/2159-8290.CD-17-1409
Thomas G: Fundamentals of Medicinal Chemistry. John Wiley & Sons, 2004
Smith CR, Dougan DR, Komandla M, Kanouni T, Knight B, Lawson JD, Sabat M, Taylor ER, Vu P, and Wyrick C: Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase. J. Med. Chem., 2015; 58(14):5437-5444 https://doi.org/10.1021/acs.jmedchem.5b00734
de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, and Pazdur R: FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3586-90. https://doi.org/10.1158/1078-0432.CCR-14-2225
Michael JP: Quinoline, quinazoline and acridone alkaloids. Nat. Prod. Rep., 2000; 17:603-620. https://doi.org/10.1039/a904850b
Kayser O, Kiderlen AF, and Croft SL: Natural products as antiparasitic drugs. Parasitol Res. 2003 Jun; 90 Suppl 2:S55-62. Epub 2003 Feb 20. https://doi.org/10.1186/1475-2832-2-S1-S55
Rueping M, Antonchick AP, and Theissmann T: A highly enantioselective Brønsted acid catalyzed cascade reaction: organocatalytic transfer hydrogenation of quinolines and their application in the synthesis of alkaloids. Angew Chem Int Ed Engl. 2006 May 26; 45(22):3683-6. https://doi.org/10.1002/anie.200600191
Kerwin SM: ChemBioOffice Ultra 2010 Suite. J. Am. Chem. Soc., 2010; 132(7):2466-2467. DOI: 10.1021/ja1005306 https://doi.org/10.1021/ja1005306
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al: Gaussian 09, Revision A.02. Gaussian, Inc., Wallingford CT, 2016.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, and Olson AJ: AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009 Dec; 30(16):2785-91. https://doi.org/10.1002/jcc.21256
Páll S., Abraham M.J., Kutzner C., Hess B., and Lindahl E. (2015) Tackling Exascale Software Challenges in Molecular Dynamics Simulations with GROMACS. In: Markidis S., Laure E. (eds) Solving Software Challenges for Exascale. EASC 2014. Lecture Notes in Computer Science, vol 8759. Springer, Cham https://doi.org/10.1007/978-3-319-15976-8_1
Berendsen HJC., Postma JPM, van Gunsteren WF, DiNola A, and Haak JR: Molecular-Dynamics with Coupling to an External Bath. Journal of Chemical Physics. 984; 81 (8):3684-3690. https://doi.org/10.1063/1.448118
Di Pierro M, Elber R, and Leimkuhler B: A Stochastic Algorithm for the Isobaric-Isothermal Ensemble with Ewald Summations for All Long-Range Forces. J Chem Theory Comput. 2015 Dec 8; 11(12):5624-37. https://doi.org/10.1021/acs.jctc.5b00648
Simulation plus., Inc.: ADMET PredictorTM. 42505 10th Street West, 2016.
Leach AR: Molecular Modelling: Principles and Applications. Prentice-Hall, Second Edition 2001.
Schlegel HB: Geometry optimization. Advanced Review 2011; 1(5):790-809. https://doi.org/10.1002/wcms.34
Cramer CJ: Essentials of Computational Chemistry: Theories and Models. John Wiley and Sons Second Edition 2004.
Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000 Jul-Aug; 44(1):235-49. https://doi.org/10.1016/S1056-8719(00)00107-6
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ: Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem. 1998; 19:1639-1662. https://doi.org/10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
Published
Abstract Display: 564 
PDF Downloads: 669 PDF Downloads: 41 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.